UPSC Prelims Practice Questions — Union Health Ministry Proposes Amendment to New Drugs and Clinical Trials Rules, 2019 to Bring Antimicrobials under Central Regulatory Oversight
Q1. With reference to the draft amendment that would bring antimicrobials within the definition of 'new drug' under the New Drugs and Clinical Trials Rules, 2019, consider the following statements: Which of the statements given above is/are correct?
- A manufacturer would have to obtain the permission of the Central Licensing Authority before it can apply to the State Licensing Authority for a manufacturing licence.
- The Central Licensing Authority would itself issue manufacturing licences for antimicrobials in place of the State Licensing Authorities.
- The reclassification is intended to ensure that evidence such as bioequivalence and stability data is examined before manufacture of an antimicrobial is licensed.
- A. 2 and 3 only
- B. 1, 2 and 3
- C. 1 and 3 only
- D. 1 only
Q2. With reference to delegated (subordinate) legislation in India, consider the following statements: Which of the statements given above is/are correct?
- Rules framed by the executive under a parent Act can be amended through a notification in the Gazette, without Parliament passing a fresh Act.
- A rule may validly enlarge the scope of its parent Act, provided the rule was first published in draft and objections were considered.
- The Committee on Subordinate Legislation examines every rule laid before Parliament before that rule can come into force.
- A. 1 and 3 only
- B. 1 only
- C. 2 and 3 only
- D. 1 and 2 only
Q3. An antimicrobial tablet contains much less active ingredient than its label states. Apart from failing to cure the patient, which one of the following best explains how such a product can worsen the problem of drug-resistant infections?
- A. It exposes microbes to sub-lethal drug levels, so that the less susceptible among them survive and multiply.
- B. It stimulates the patient's immune system to produce antibodies that neutralise the drug in later courses.
- C. It prompts each microbe to deliberately mutate in response to the drug, producing resistance on demand.
- D. It supplies microbes with drug molecules that they break down and use as an extra source of nutrition.
Q4. Consider the following statements: Which of the following is correct in respect of the above statements?
- Drug-resistant bacteria can cause infection in a person who has never taken the antimicrobial concerned.
- Antimicrobial resistance is a property acquired by the human body, which becomes habituated to a drug after repeated use.
- A. Both Statement-I and Statement-II are correct and Statement-II explains Statement-I
- B. Both Statement-I and Statement-II are correct, but Statement-II does not explain Statement-I
- C. Statement-I is correct, but Statement-II is incorrect
- D. Statement-I is incorrect, but Statement-II is correct
Q5. With reference to quality evidence for generic medicines, consider the following statements: Which of the statements given above are correct?
- A bioequivalence study serves as a bridge between a generic product and a comparator product whose safety and efficacy have already been established.
- A product shown to remain stable over its shelf life is thereby shown to be bioequivalent to the comparator product.
- Stability testing is the basis for assigning a shelf life and recommended storage conditions to a finished product.
- Because a drug that degrades during storage may deliver less than its labelled dose, stability data bear on efficacy and not merely on appearance.
- A. 2 and 4 only
- B. 1 and 3 only
- C. 1, 2, 3 and 4
- D. 1, 3 and 4 only
Q6. WHO estimates that in 2021 bacterial antimicrobial resistance was 'associated with' about 4.71 million deaths but 'directly responsible for' about 1.14 million. Which one of the following best explains why the first figure is so much larger than the second?
- A. It includes deaths from adverse reactions to antimicrobials, which the second figure excludes.
- B. It includes deaths from viral and fungal infections, while the second covers only bacterial infections.
- C. It includes people with a resistant infection who might have died even had it been drug-susceptible.
- D. It is a projection for future years, while the second is counted from hospital death records.
Q7. Consider the following assertion: 'Tightening quality control over antimicrobials is a measure to contain antimicrobial resistance, and not merely a measure to protect individual patients.' Which of the following statements support the above assertion?
- Taking antibiotics when they are not needed is one of the leading drivers of antimicrobial resistance.
- Products containing less active ingredient than stated expose microbes to sub-therapeutic drug concentrations that can favour resistant strains.
- Limited access to vaccines and diagnostics contributes to the antimicrobial resistance crisis.
- Laboratory studies have shown that a degraded antimicrobial can select for resistance genes.
- A. 2, 3 and 4 only
- B. 2 and 4 only
- C. 1, 3 and 4 only
- D. 1 and 2 only